– USA, MD – Veralox Therapeutics, a biotechnology company developing first-in-class small molecule therapeutics that treat the underlying pathologies of diseases with significant unmet medical needs, today announced the appointment of Alex Martin as Chairman of the Board of Directors.
“I am thrilled to welcome Alex as Chairman of our Board of Directors,” said CEO, Dr. Jeffrey Strovel. “He is an accomplished industry leader who brings a strong track record in operational, business and drug development experience. Alex’s deep understanding of our industry and keen strategic insights will bring an important perspective to the Board as we transition to a clinical stage company with multiple products in development.”
About Alex Martin
Mr. Martin brings to the Chairman’s role over 25 years of experience in senior executive roles in the life sciences industry, with a focus on business development, operations, and financing. He is currently the CEO, Palladio Biosciences, a clinical-stage biopharmaceutical company developing medicines for orphan diseases of the kidney. Mr. Martin was previously CEO, Realm Therapeutics, which was acquired by ESSA Pharma in July 2019, and has held executive roles at biopharmaceutical companies including Intercept Pharmaceuticals as COO and BioXell as CFO. He began his career at SmithKline Beecham and later became VP, Global Business Development & Licensing at Novartis.
“It’s an honor to be appointed Chairman and I’m excited for the opportunity to leverage my experience to provide additional perspectives and insights at such an important time in Veralox’s evolution,” added Alex Martin. “Heparin-induced thrombocytopenia is a life-threatening disease where the only approved treatment still carries the risk of significant bleeding and mortality, and Veralox’s lead candidate, VLX-1005, could be a game changer for people suffering from this condition. I look forward to working with Jeff and the entire Veralox Board to further develop this opportunity.”
Mr. Martin received his B.A. from Cornell University and an M.B.A. from Harvard University.
About Veralox Therapeutics
VERALOX Therapeutics Inc. is developing first-in-class therapeutics that target the underlying pathologies of diseases with unmet medical needs. The company’s lead candidate, VLX-1005, will be developed initially to treat patients with heparin-induced thrombocytopenia and HIT with thrombosis. Second generation therapeutic products are under development for type 1 diabetes as well as other immune-mediated and inflammatory diseases.
For more information : https://veralox.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.